Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS |
Hidradenitis Suppurativa | Phase3 | Argentina Australia Canada United States View all |
NCT07665437 |
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) |
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF) | Phase3 | Argentina Australia China India Italy Japan Malaysia Poland South Korea Switzerland Taiwan Turkey (Türkiye) United States View all |
NCT07357727 |
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) |
Cardiovascular Disease and Lipoprotein(a) | Phase3 | Argentina Belgium Brazil Bulgaria Canada China Colombia Czechia Denmark France Germany Greece Hong Kong Hungary Iceland India Italy Japan Mexico Netherlands Norway Poland Puerto Rico Romania Russia Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan Turkey (Türkiye) United Kingdom United States View all |
NCT07517263 |
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo |
Non-segmental Vitiligo | Phase2 | Argentina Australia Canada China France Germany India Italy Japan Netherlands Spain United States View all |
NCT07431177 |
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease |
Huntington Disease | Phase3 | Argentina Australia Belgium Bulgaria Canada China Czechia France Germany Hungary Israel Japan Netherlands Romania Saudi Arabia Slovakia South Korea Spain Switzerland Taiwan United Kingdom United States View all |
NCT07326709 |
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis |
Secondary Progressive Multiple Sclerosis (SPMS) | Phase3 | Argentina Australia Austria Belgium Brazil Bulgaria Canada China Colombia Croatia Czechia Denmark Estonia France Germany Greece Hungary India Israel Italy Lithuania Mexico Netherlands Poland Portugal Romania Slovakia South Africa Spain Switzerland United Kingdom United States View all |
NCT07225504 |
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN |
Primary Immunoglobulin A Nephropathy (IgAN) | Phase3 | Argentina Australia China Hong Kong Israel Japan Saudi Arabia United States View all |
NCT06994845 |
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. |
Relapsing Multiple Sclerosis | Phase3 | Argentina Australia Belgium Brazil Canada Czechia Denmark France Germany Greece Italy Mexico Portugal Slovakia South Africa Spain Switzerland United Kingdom United States View all |
NCT06846281 |
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. |
Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease | Phase3 | Argentina Australia Canada Malaysia Mexico South Korea Spain Taiwan United States View all |
NCT06858319 |
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN |
Glomerulonephritis, IGA, Immunoglobulin A Nephropathy | Phase2 | Argentina Israel Malaysia Saudi Arabia United States View all |
NCT06797518 |